![]() ![]() | Esser, N., Mongovin, S. M., Parilla, J., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J. J., Akter, R., Hull, R. L., & Zraika, S. (01 March 2022). Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction. American Journal of Physiology - Endocrinology and Metabolism, 322 (3), 307-E318. doi:10.1152/ajpendo.00234.2021 ![]() |
![]() ![]() | Kahn, S. E., Chen, Y.-C., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021). The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 42 (5), 528-583. doi:10.1210/endrev/bnab021 ![]() |
![]() ![]() | Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020). Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 63 (10), 2007-2021. doi:10.1007/s00125-020-05245-x ![]() |
![]() ![]() | ESSER, N., Legrand, S., Piette, J., SCHEEN, A., & PAQUOT, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. doi:10.1016/j.diabres.2014.04.006 ![]() |
![]() ![]() | ESSER, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (November 2013). Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 56, 2487-2497. doi:10.1007/s00125-013-3023-9 ![]() |
![]() ![]() | Akter, R., Hogan, M. F., Esser, N., Barrow, B. M., Castillo, J. J., Boyko, E. J., Templin, A. T., Hull, R. L., Zraika, S., & Kahn, S. E. (05 February 2025). Increased Steroidogenic Acute Regulatory Protein Contributes to Cholesterol-induced β-Cell Dysfunction. Endocrinology, 166 (3). doi:10.1210/endocr/bqaf027 ![]() |
![]() ![]() | Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Fountaine, B. S., Castillo, J. J., El-Osta, A., Manathunga, L., Zhyvoloup, A., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (September 2024). The Islet Tissue Plasminogen Activator/Plasmin System is Upregulated with Human Islet Amyloid Polypeptide Aggregation and Protects Beta Cells from Aggregation-Induced Toxicity. Diabetologia, 67 (9), 1897-1911. doi:10.1007/s00125-024-06161-0 ![]() |
![]() ![]() | L'homme, L., Sermikli, B. P., Haas, J. T., Fleury, S., Quemener, S., Guinot, V., Barreby, E., Esser, N., Caiazzo, R., Verkindt, H., Legendre, B., Raverdy, V., Cheval, L., Paquot, N., Piette, J., Legrand, S., Aouadi, M., Pattou, F., Staels, B., & Dombrowicz, D. (21 August 2024). Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH. Nature Communications, 15 (1), 7173. doi:10.1038/s41467-024-51078-2 ![]() |
![]() ![]() | Esser, N., Mongovin, S. M., Barrow, B. M., & Zraika, S. (02 July 2024). Gut-Specific Neprilysin Deletion Protects Against Fat-Induced Insulin Secretory Dysfunction In Male Mice. Endocrinology, 165 (8), 080. doi:10.1210/endocr/bqae080 ![]() |
![]() ![]() | Scheen, A., Luyckx, F., Esser, N., & Paquot, N. (March 2024). Vignette diagnostique de l’étudiant. Ne pas négliger le syndrome métabolique. Revue Médicale de Liège, 79 (3), 191 - 194. ![]() |
![]() ![]() | Mukherjee, N., Contreras, C. J., Lin, L., Colglazier, K. A., Mather, E. G., Kalwat, M. A., Esser, N., Kahn, S. E., & Templin, A. T. (11 January 2024). RIPK3 promotes islet amyloid-induced β-cell loss and glucose intolerance in a humanized mouse model of type 2 diabetes. Molecular Metabolism, 80, 101877. doi:10.1016/j.molmet.2024.101877 ![]() |
![]() ![]() | Esser, N., & Paquot, N. (23 August 2023). Actualisation des recommandations nutritionnelles dans le traitement du diabète de type 2. Revue Médicale Suisse, 19 (838), 1486 - 1490. doi:10.53738/REVMED.2023.19.838.1486 ![]() |
![]() ![]() | Esser, N., Mongovin, S. M., Mundinger, T. O., Barrow, B. M., & Zraika, S. (10 August 2023). Neprilysin deficiency reduces hepatic gluconeogenesis in high fat-fed mice. Peptides, 168, 171076. doi:10.1016/j.peptides.2023.171076 ![]() |
![]() ![]() | Esser, N., Mundinger, T. O., Barrow, B. M., & Zraika, S. (13 March 2023). Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice. Endocrinology, 164 (5). doi:10.1210/endocr/bqad055 ![]() |
![]() ![]() | Castillo, J. J., Aplin, A. C., Hackney, D. J., Hogan, M. F., Esser, N., Templin, A. T., Akter, R., Kahn, S. E., Raleigh, D. P., Zraika, S., & Hull, R. L. (October 2022). Islet amyloid polypeptide aggregation exerts cytotoxic and proinflammatory effects on the islet vasculature in mice. Diabetologia, 65 (10), 1687 - 1700. doi:10.1007/s00125-022-05756-9 ![]() |
![]() ![]() | Esser, N., & PAQUOT, N. (May 2022). Inflammation, obésité et diabète de type 2. Rôle de l’inflammasome NLRP3 et du microbiote intestinal. Revue Médicale de Liège, 77 (5-6), 310-315. ![]() |
![]() ![]() | SCHEEN, A., LUYCKX, F., Esser, N., LAMPROYE, A., DELWAIDE, J., & PAQUOT, N. (May 2022). Stéatohépatite non alcoolique (NASH) : un modèle d’inflammation métabolique («métaflammation»). Revue Médicale de Liège, 77 (5-6), 316-322. ![]() |
![]() ![]() | Esser, N., Mongovin, S. M., Parilla, J., Barrow, B. M., Mundinger, T. O., Fountaine, B. S., Larmore, M. J., Castillo, J. J., Akter, R., Hull, R. L., & Zraika, S. (01 March 2022). Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with β-cell dysfunction. American Journal of Physiology - Endocrinology and Metabolism, 322 (3), 307-E318. doi:10.1152/ajpendo.00234.2021 ![]() |
![]() ![]() | Esser, N., Schmidt, C., Barrow, B. M., Cronic, L., Hackney, D. J., Mongovin, S. M., Hogan, M. F., Templin, A. T., Castillo, J. J., Hull, R. L., & Zraika, S. (2022). Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice. Frontiers in Endocrinology, 13, 888867. doi:10.3389/fendo.2022.888867 ![]() |
![]() ![]() | Wilkin, C., Colonval, M., Dehairs, J., Esser, N., Iovino, M., Gianfrancesco, M. A., FADEUR, M., Swinnen, J. V., PAQUOT, N., Piette, J., & Legrand, S. (2021). New insights on the PBMCs phospholipidome in obesity demonstrate modulations associated with insulin resistance and glycemic status. Nutrients. doi:10.3390/nu13103461 ![]() |
![]() ![]() | Templin, A. T., Schmidt, C., Hogan, M. F., Esser, N., Kitsis, R. N., Hull, R. L., Zraika, S., & Kahn, S. E. (2021). Loss of apoptosis repressor with caspase recruitment domain (ARC) worsens high fat diet-induced hyperglycemia in mice. Journal of Endocrinology, 251 (2), 125-135. doi:10.1530/JOE-20-0612 ![]() |
![]() ![]() | Esser, N., Utzschneider, K. M., & Kahn, S. E. (2021). On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes: Reply to Johnson JD [letter]. Diabetologia, 64 (10), 2345-2347. doi:10.1007/s00125-021-05511-6 ![]() |
![]() ![]() | Esser, N., & PAQUOT, N. (2021). Intérêt de la combinaison sacubitril/valsartan dans le diabète de type 2. Revue Médicale Suisse, 17, 1418-1422. ![]() |
![]() ![]() | Hogan, M. F., Hackney, D. J., Aplin, A. C., Mundinger, T. O., Larmore, M. J., Castillo, J. J., Esser, N., Zraika, S., & Hull, R. L. (2021). SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice. Journal of Endocrinology, 248 (2), 95-106. doi:10.1530/JOE-20-0354 ![]() |
![]() ![]() | Kahn, S. E., Chen, Y.-C., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021). The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 42 (5), 528-583. doi:10.1210/endrev/bnab021 ![]() |
![]() ![]() | Kjeldsen, S. A. S., Hansen, L. H., Esser, N., Mongovin, S., Winther-Sørensen, M., Galsgaard, K. D., Hunt, J. E., Kissow, H., Ceutz, F. R., Terzic, D., Mark, P. D., Plomgaard, P., Goetze, J. P., Goossens, G. H., Blaak, E. E., Deacon, C. F., Rosenkilde, M. M., Zraika, S., Holst, J. J., & Wewer Albrechtsen, N. J. (2021). Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. Journal of the Endocrine Society, 5 (9), 084. doi:10.1210/jendso/bvab084 ![]() |
![]() ![]() | Templin, A. T., Mellati, M., Meier, D. T., Esser, N., Hogan, M. F., Castillo, J. J., Akter, R., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia, 63 (11), 2385-2395. doi:10.1007/s00125-020-05232-2 ![]() |
![]() ![]() | Esser, N., & Zraika, S. (2020). Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19. British Journal of Cardiology, 27 (4), 109-111. doi:10.5837/bjc.2020.031 ![]() |
![]() ![]() | Esser, N., Utzschneider, K. M., & Kahn, S. E. (2020). Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 63 (10), 2007-2021. doi:10.1007/s00125-020-05245-x ![]() |
![]() ![]() | Templin, A. T., Mellati, M., Soininen, R., Hogan, M. F., Esser, N., Castillo, J. J., Zraika, S., Kahn, S. E., & Hull, R. L. (2019). Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein Engineering, Design and Selection, 32 (2), 95-102. doi:10.1093/protein/gzz041 ![]() |
![]() ![]() | Esser, N., & Zraika, S. (2019). Neprilysin inhibition: a new therapeutic option for type 2 diabetes? Diabetologia, 62 (7), 1113-1122. doi:10.1007/s00125-019-4889-y ![]() |
![]() ![]() | Hogan, M. F., Ziemann, M., K N, H., Rodriguez, H., Kaspi, A., Esser, N., Templin, A. T., El-Osta, A., & Kahn, S. E. (2019). RNA-seq-based identification of Star upregulation by islet amyloid formation. Protein Engineering, Design and Selection, 32 (2), 67-76. doi:10.1093/protein/gzz022 ![]() |
![]() ![]() | Esser, N., Barrow, B. M., Choung, E., Shen, N. J., & Zraika, S. (2018). Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner. Islets, 10 (5), 175-180. doi:10.1080/19382014.2018.1502521 ![]() |
![]() ![]() | Scheen, A., ESSER, N., & Paquot, N. (2015). Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes and Metabolism. doi:10.1016/j.diabet.2015.02.003 ![]() |
![]() ![]() | Esser, N., Paquot, N., & Scheen, A. (2015). Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opinion on Investigational Drugs, 24 (3), 283-307. doi:10.1517/13543784.2015.974804 ![]() |
![]() ![]() | ESSER, N., Paquot, N., & Scheen, A. (2015). Inflammatory markers and cardiometabolic diseases. Acta Clinica Belgica, 70 (3), 193-9. doi:10.1179/2295333715Y.0000000004 ![]() |
![]() ![]() | Legrand-Poels, S., Esser, N., L'Homme, L., SCHEEN, A., PAQUOT, N., & Piette, J. (2014). Free fatty acids as modulators of the NLRP3 inflammasome in obesity / type 2 diabetes. Biochemical Pharmacology. doi:10.1016/j.bcp.2014.08.013 ![]() |
![]() ![]() | Esser, N., SCHEEN, A., & PAQUOT, N. (01 April 2014). Metabolically healthy overweight and obesity. Annals of Internal Medicine, 160 (7), 514. ![]() |
![]() ![]() | ESSER, N., Legrand, S., Piette, J., SCHEEN, A., & PAQUOT, N. (2014). Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Research and Clinical Practice. doi:10.1016/j.diabres.2014.04.006 ![]() |
![]() ![]() | ESSER, N., Legrand-Poels, S., Piette, J., Paquot, N., & Scheen, A. (2014). Inflammasome NLRP3 et graisse viscerale. Revue Médicale de Liège, 69 Spec No, 57-61. ![]() |
![]() ![]() | L'Homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., & Legrand, S. (November 2013). Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages. Journal of Lipid Research, 54, 2998-3008. doi:10.1194/jlr.M037861 ![]() |
![]() ![]() | ESSER, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (November 2013). Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia, 56, 2487-2497. doi:10.1007/s00125-013-3023-9 ![]() |
![]() ![]() | DE SENY, D., COBRAIVILLE, G., CHARLIER, E., NEUVILLE, S., Esser, N., MALAISE, D., MALAISE, O., Calvo, F., RELIC, B., & MALAISE, M. (2013). Acute-phase serum amyloid a in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS ONE. doi:10.1371/journal.pone.0066769 ![]() |
![]() ![]() | DE FLINES, J., RORIVE, M., Esser, N., Paquot, N., Luyckx, F., & SCHEEN, A. (2013). La vignette diagnostique de l'etudiant. Mise au point d'un patient consultant pour obesite. Revue Médicale de Liège, 68 (3), 148-53. ![]() |
![]() ![]() | Esser, N., Paquot, N., & SCHEEN, A. (2011). Diabete de type 2 et medicaments anti-inflammatoires: nouvelles perspectives therapeutiques? Revue Médicale Suisse, 7 (306), 1614-8, 1620. ![]() |
![]() ![]() | Esser, N., Paquot, N., & Scheen, A. (2010). Aptitude physique versus adiposité : aspects physiopathologiques et impacts cardio-métaboliques chez le sujet adulte non diabétique. Médecine des Maladies Métaboliques, 4, 291-298. doi:10.1016/S1957-2557(10)70062-6 ![]() |
![]() ![]() | Esser, N., Paquot, N., & Scheen, A. (2010). Aptitude physique versus adiposité : impacts cardio-métaboliques respectifs chez l’enfant/adolescent et chez la personne âgée. Médecine des Maladies Métaboliques, 4, 395-401. doi:10.1016/S1957-2557(10)70083-3 ![]() |
![]() ![]() | ESSER, N., Paquot, N., & Scheen, A. (2010). "Fitness" versus "fatness": impacts cardio-metaboliques respectifs aux differents ages de la vie. Revue Médicale de Liège, 65 (4), 199-205. ![]() |
![]() ![]() | ESSER, N., Paquot, N., & Scheen, A. (March 2009). Sujets « métaboliquement sains », bien qu’obèses. Première partie: diagnostic, physiopathologie et prévalence. Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité, 3, 56-65. doi:10.1007/s11690-009-0170-8 ![]() |
![]() ![]() | ESSER, N., & Scheen, A. (2009). Sujets obèses sans anomalies métaboliques. Revue Médicale de Liège, 64 (3), 148-157. ![]() |
![]() ![]() | Beck, E., ESSER, N., Paquot, N., & Scheen, A. (2009). Sujets de poids normal «métaboliquement obèses» et sujets obèses «métaboliquement sains». Revue Médicale de la Suisse Romande, 5, 1644-1649. ![]() |
![]() ![]() | Esser, N., PAQUOT, N., & SCHEEN, A. (2009). Sujets « métaboliquement sains », bien qu’obèses 2ème partie : pronostic et prise en charge. Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité, 4, 134-141. doi:10.1007/s11690-009-0188-y ![]() |
![]() ![]() | Esser, N. (2023). Gut-Specific Neprilysin Deletion Increases Insulin Secretion in High-Fat–Fed Mice. Diabetes, 72(Supplement_1), 1546. ![]() |
![]() ![]() | Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Castillo, J. J., Raleigh, D. P., Zraika, S., Hull, R. L., & Kahn, S. E. (September 2022). Islet macrophage depletion does not prevent amyloid-induced upregulation of tissue plasminogen activator (tPA). Diabetologia, 65 (Suppl 1), 1-1469. ![]() |
![]() ![]() | AKTER, R., HOGAN, M. F., Esser, N., CASTILLO, J. J., HULL-MEICHLE, R. L., ZRAIKA, S., & KAHN, S. E. (01 June 2022). Cholesterol Accumulation in Islets Increases Steroidogenic Acute Regulatory (StAR) Protein Expression and Decreases Islet Cell Viability and ß-Cell Function. Diabetes, 71 (Supplement_1), 1457. doi:10.2337/db22-1457-p ![]() |
![]() ![]() | HOGAN, M. F., Esser, N., TEMPLIN, A. T., CASTILLO, J. J., AKTER, R., HULL, R. L., KAHN, S. E., & ZRAIKA, S. (01 June 2021). Statin Exposure Increases Star (Steroidogenic Acute Regulatory Protein) Expression in Islets: A Novel Mechanism for ß-Cell Dysfunction and Increased Diabetes Risk? Diabetes, 70 (Supplement_1), 130. doi:10.2337/db21-130-or ![]() |
![]() ![]() | Castillo, J. J., Aplin, A., Hogan, M. F., Templin, A. T., Esser, N., Akter, R., & Hull, R. L. (2021). The Proinflammatory but Not Cytotoxic Effect of Aggregated IAPP on Islet Endothelial Cells Requires TLR2/4 Signaling. Diabetes, 70 (Suppl 1), 1238. ![]() |
![]() ![]() | Castillo, J. J., Hogan, M. F., Aplin, A., Esser, N., Templin, A. T., Hull, R. L., Zraika, S., & Kahn, S. E. (2020). Hyaluronan produced by inflamed islet endothelial cells contributes to hIAPP aggregation. Diabetes, 69 (Suppl 1), 2043. ![]() |
![]() ![]() | Templin, A. T., Schmidt, C. R., Hogan, M. F., Esser, N., Kitsis, R., Hull, R. L., Zraika, S., & Kahn, S. E. (2020). Loss of apoptosis repressor with caspase recruitment domain promotes high-fat diet induced hyperglycemia in vivo. Diabetes, 69 (Suppl 1), 2042. ![]() |
![]() ![]() | Esser, N., Schmidt, C. R., Barrow, B., Cronic, L., Hackney, D. J., Mongovin, S., Hull, R. L., & Zraika, S. (2020). Effect of LCZ696 and its components sacubitril and valsartan on insulin secretion and glucose homeostasis in mice. Diabetes, 69 (Suppl 1), 1797. ![]() |
![]() ![]() | Esser, N., Hogan, M. F., Templin, A. T., Castillo, J. J., Raleigh, D., Edgar, J. S., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Plasmin-mediated cleavage of human islet amyloid polypeptide (hIAPP) protects beta-cells from amyloid-induced toxicity. Diabetes, 69 (Suppl 1), 2039. ![]() |
![]() ![]() | Hogan, M. F., Esser, N., Templin, A. T., Castillo, J. J., Zraika, S., Hull, R. L., & Kahn, S. E. (2020). Chronic activation of CREB by islet amyloid increases Star (steroidogenic acute regulatory protein). Diabetes, 69 (Suppl 1), 2040. ![]() |
![]() ![]() | Hogan, M. F., Esser, N., Templin, A. T., Zraika, S., Hull, R. L., El-Osta, S., & Kahn, S. E. (2019). Increased StAR (steroidogenic acute regulatory protein) is detrimental to ß cells and promotes mitochondrial dysfunction. Diabetes, 68 (Suppl 1), 2125. ![]() |
![]() ![]() | Esser, N., Mundinger, T. O., Barrow, B., Mongovin, S., & Zraika, S. (2019). Acute inhibition of intestinal neprilysin enhances glucose-stimulated insulin secretion in mice. Diabetes, 68 (Suppl 1), 1829. ![]() |
![]() ![]() | Esser, N., Hogan, M. F., Aplin, A., Templin, A. T., El-Osta, S., Raleigh, D., Edgar, J. S., Zraika, S., Hull, R. L., & Kahn, S. E. (2019). The tissue plasminogen activator (tPA)/plasmin system reduces amyloid formation by cleaving human islet amyloid polypeptide (hIAPP). Diabetes, 68 (Suppl 1), 2124. ![]() |
![]() ![]() | Templin, A. T., Mellati, M., Zeman-Meier, D., Hogan, M. F., Esser, N., Zraika, S., Hull, R. L., & Kahn, S. E. (2019). Physiological concentrations of IL-1 beta promote islet amyloid deposition by increasing beta-cell secretion of human islet amyloid polypeptide. Diabetes, 68 (Suppl 1), 2126. ![]() |
![]() ![]() | Esser, N., Hogan, M. F., Templin, A. T., Ziemann, M., El-Osta, A., Zraika, S., Hull, R. L., & Kahn, S. E. (2018). Tissue plasminogen activator (tPA) expression is increased by islet amyloid formation in vitro. Diabetes, 67 (Suppl 1), 2107. ![]() |
![]() ![]() | Parilla, J. P., Mongovin, S., Barrow, B., Esser, N., & Zraika, S. (2018). Pharmacological neprilysin inhibition improves glucose homeostasis in a mouse model of type 2 diabetes. Diabetes, 67 (Suppl 1), 1825. ![]() |
![]() ![]() | Gianfrancesco, M., Dehairs, J., L'Homme, L., Colonval, M., Piette, J., Swinnen, J., Paquot, N., Esser, N., & Legrand, S. (2017). The saturation of membrane phospholipids would be a trigger for K+ efflux and NLRP3 inflammasome activation in human monocytes/macrophages. Diabetologia. ![]() |
![]() ![]() | Gianfrancesco, M., Dehairs, J., Bloch, K., L'homme, L., Piette, J., Swinnen, J., Paquot, N., Esser, N., & Legrand, S. (August 2016). Involvement of membrane remodelling induced by fatty acids in the regulation of the NLRP3 inflammasome activity in human macrophages. Diabetologia, 59 (Supplement 1), 291. ![]() |
![]() ![]() | Esser, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., MOUTSCHEN, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (2013). Increased Inflammasome and Caspase-1 Activation in Visceral adipose tissue from Metabolically Unhealthy Obese compared to Metabolically Healthy Obese subjects. Diabetes, (62/suppl.1), 555. ![]() |
![]() ![]() | Esser, N., L'Homme, L., DE ROOVER, A., KOHNEN, L., SCHEEN, A., Moutschen, M., Piette, J., Legrand-Poels, S., & PAQUOT, N. (March 2013). Différences d’activité de l’inflammasome NLRP3 entre sujets obèses avec et sans anomalies métaboliques. Diabetes and Metabolism, 39 (suppl 1), 102. ![]() |
Langhendries, L., Hakobyan, M., Manathunga, L., Legrand, S., Paquot, N., Kahn, S. E., Abedini, A., Raleigh, D. P., & Esser, N. (03 April 2025). La mutation S20G dans le polypeptide amyloïde humain des îlots (hIAPP) exacerbe l'activation de l'inflammasome NLRP3 par hIAPP dans les macrophages [Paper presentation]. Société francophone du diabète Congrès Annuel 2025, Paris, France. ![]() |
Wilkin, C., Esser, N., & Legrand, S. (07 February 2025). Impact of bariatric surgery on human peripheral blood iNKT cells [Paper presentation]. Winter Symposium Obesity 2025, De Haan, Belgium. ![]() |
Esser, N., Mongovin, S., Barrow, B. M., & Zraika, S. (21 March 2024). L’invalidation sélective de la néprilysine dans les entérocytes augmente la sécrétion d’insuline chez les souris sous régime riche en graisses [Paper presentation]. Congrès Annuel de la Société Francophone du Diabète, Toulouse, France. ![]() |
![]() ![]() | Langhendries, L., Habokyan, M., Manathunga, L., Legrand, S., Paquot, N., Kahn, S. E., Abedini, A., Raleigh, D. P., & Esser, N. (03 April 2025). La mutation S20G dans le polypeptide amyloïde humain des îlots (hIAPP) exacerbe l'activation de l'inflammasome NLRP3 par hIAPP dans les macrophages [Poster presentation]. Société francophone du diabète congrès annuel 2025, Paris, France. ![]() |
![]() ![]() | Esser, N., Hogan, M. F., Templin, A. T., Akter, R., Castillo, J. J., Zraika, S., Hull, R. L., & Kahn, S. E. (June 2022). Macrophage Depletion Does Not Prevent Tissue Plasminogen Activator (tPA) Upregulation in Islets with Amyloid Deposition [Poster presentation]. Cell Symposium: Translational Immunometabolism, Bâle, Switzerland. ![]() |
Esser, N., Barrow, B. M., Mundinger, T. O., Parilla, J. H., & Zraika, S. (September 2018). Contribution of islet and intestinal neprilysin in modulating beta-cell function [Poster presentation]. The Islet Biology Workshop at Vanderbilt, Nashville, United States. ![]() |